Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema

Laryngoscope

Volumn 125, Issue 6, 2015, Pages E198-E202

  Greve, Jens ^a   Bas, Murat ^b   Hoffmann, Thomas K ^a   Schuler, Patrick J ^a   Weller, Patrick ^c   Kojda, Georg ^d   Strassen, Ulrich ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Angioedema; angiotensin converting enzyme inhibitor; bradykinin; C1 esterase inhibitor concentrate; edema; quincke edema

Indexed keywords

CLEMASTINE; COMPLEMENT COMPONENT C1S INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; METHYLPREDNISOLONE; RAMIPRIL;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE STUDY; CAUCASIAN; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FACE; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTENSIVE CARE UNIT; INTUBATION; ISCHEMIC HEART DISEASE; LARYNX; LIP; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RETREATMENT; TONGUE; TRACHEOTOMY; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL; GASTROINTESTINAL DISEASES; MIDDLE AGED; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASES;

ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATORY TRACT DISEASES;

EID: 84929703881     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.25113     Document Type: Article

References (23)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD,. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462. doi: 10.1056/NEJM199311113292004.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G,. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153. doi: 10.1056/NEJM200001203420301.
3. Slater EE, Merrill DD, Guess HA, et al., Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA J Am Med Assoc 1988; 260: 967-970.
4. Pfeffer MA, McMurray JJ, Velazquez EJ, et al., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
5. Bas M, Kojda G, Bier H, Hoffmann TK,. [ACE inhibitor-induced angioedema in the head and neck region. A matter of time?]. HNO 2004; 52: 886-890. doi: 10.1007/s00106-003-1017-5.
6. Beltrami L, Zingale LC, Carugo S, Cicardi M,. Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin Drug Saf 2006; 5: 643-649. doi: 10.1517/14740338.5.5.643.
7. Beltrami L, Zanichelli A, Zingale L, Vacchini R, Carugo S, Cicardi M,. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29: 2273-2277. doi: 10.1097/HJH.0b013e32834b4b9b.
8. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G,. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62: 842-856. doi: 10.1111/j.1398-9995.2007.01427.x.
9. Bas M, Hoffmann TK, Kojda G,. Evaluation and management of angioedema of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2006; 14: 170-175. doi: 10.1097/01.moo.0000193202.85837.7d.
10. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A,. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-1697. doi: 10.1016/S0140-6736(97)09137-X.
11. Maurer M, Bader M, Bas M, et al., New topics in bradykinin research. Allergy 2011; 66: 1397-1406. doi: 10.1111/j.1398-9995.2011.02686.x.
12. Bas M, Greve J, Stelter K, et al., Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010; 56: 278-282. doi: 10.1016/j.annemergmed.2010.03.032.
13. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE,. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-1063. doi: 10.1172/JCI14211.
14. Davis AE, Bissler JJ, Cicardi M,. Mutations in the C1 inhibitor gene that result in hereditary angioneurotic edema. Behring Inst Mitt 1993;(93): 313-320.
15. Davis AE,. The pathogenesis of hereditary angioedema. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 2003; 29: 195-203. doi: 10.1016/j.transci.2003.08.012.
16. Agostoni A, Cicardi M,. Drug-induced angioedema without urticaria. Drug Saf Int J Med Toxicol Drug Exp 2001; 24: 599-606.
17. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffré D, Nussberger J,. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999; 44: 21-25.
18. Bas M, Hoffmann T, Kojda G, Bier H,. Das ACE-Hemmer-induzierte Angioödem. Laryngo-Rhino-Otol 2007; 86: 804-812. doi: 10.1055/s-2007-966932.
19. Kaplan AP, Greaves MW,. Angioedema. J Am Acad Dermatol 2005; 53: 373-388; quiz 389-392. doi: 10.1016/j.jaad.2004.09.032.
20. Farkas H, Jakab L, Temesszentandrasi G, et al., Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120: 941-947. doi: 10.1016/j.jaci.2007.06.026.
21. Craig TJ, Levy RJ, Wasserman RL, et al., Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-808. doi: 10.1016/j.jaci.2009.07.017.
22. Zuraw BL, Kalfus I,. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012; 125: 938.e1-938.e7. doi: 10.1016/j.amjmed.2012.02.020.
23. Farrell C, Hayes S, Relan A, van Amersfoort ES, Pijpstra R, Hack CE,. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol 2013; 76: 897-907. doi: 10.1111/bcp.12132.